Home Journals Progress in Chemistry
Progress in Chemistry

Abbreviation (ISO4): Prog Chem      Editor in chief: Jincai ZHAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
Review

Functionalization and Application of Polymer-Modified Proteins

  • Jiang Wan ,
  • Jingze Zhang ,
  • Hongling Chen ,
  • Hanmei Shen ,
  • Zhen Wang ,
  • Chun Zhang , *
Expand
  • College of life science and technology, Huazhong University of Science and Technology, Wuhan 430000, China

Received date: 2023-07-10

  Revised date: 2023-10-18

  Online published: 2024-02-23

Supported by

National Natural Science Foundation of China(22275062)

National Natural Science Foundation of China(22005110)

Undergraduates Research Training Program(S202310487273)

Abstract

As a kind of important biological macromolecules, proteins have been widely used in chemical and medical fields, such as biocatalysis, drug delivery, and molecular imaging due to their special three-dimensional spatial structure and high catalytic activity. However, there are a series of problems in the practical application of proteins. For example, proteins are easily inactivated in extreme environments. Protein drugs have strong immunogenicity in vivo, which leads to short half-life of drugs and causes adverse reactions in patients easily. Their low solubility in organic solvents limits their use in organic solvents. In order to solve the above problems, researchers have developed methods such as protein engineering and co-immobilization, but there are corresponding shortcomings. Polymer modification is one of the important methods, which can improve the properties of proteins from many aspects and expand the application of proteins. From this point of view, this review focuses on the latest research and classical literature on polymer-modified proteins, and introduces their ingenious modification methods to synthesize materials with excellent properties. The principle, practical application, existing problems and solutions of improving protein stability and activity, immunogenicity, solubility and self-assembly by polymer modification are summarized. On this basis, the challenges and possible development trends in the commercial and clinical translation of this strategy are analyzed.

Contents

1 Introduction

2 Stability and activity

2.1 Stability to temperature and pH

2.2 Stability to protease hydrolysis

2.3 Stability of chemical denaturants

2.4 Enhanced enzyme activity

2.5 Regulation of enzyme activity

3 Immunogenicity

4 Solubility

5 Self-assembly

5.1 Drug delivery

5.2 Molecular imaging

6 Conclusion and outlook

Cite this article

Jiang Wan , Jingze Zhang , Hongling Chen , Hanmei Shen , Zhen Wang , Chun Zhang . Functionalization and Application of Polymer-Modified Proteins[J]. Progress in Chemistry, 2024 , 36(3) : 416 -429 . DOI: 10.7536/PC230706

1 Introduction

Protein is an important class of biological macromolecules, known as the main undertaker of life activities. It has a wide range of applications in various fields: protein drugs are used in the treatment of many diseases; Enzymes are ideal biocatalysts for industrial production; Antibodies play a major role in molecular detection and drug targeting. However, there are also many problems in the application of proteins: the structure is easily destroyed, and its activity is reduced or even lost; It has strong immunogenicity and is easily recognized, attacked and eliminated by the immune system as a foreign antigen; It is difficult to dissolve in organic solvents and limits the scope of application[1~3].
Many methods have been applied to solve the above problems. For example, finding special natural proteins from extreme environments, protein engineering based on random or site-directed mutagenesis, and protein immobilization are common methods to improve protein function in the early stage[4~6]. These methods can improve the stability of proteins to a certain extent, but it takes a lot of manpower, material resources and time to find proteins with superior performance[7]. Nanostructures formed by self-assembly of proteins and inorganic components can enhance the activity and stability of proteins, but the poor biocompatibility of heavy metal ions limits their application[8,9]. The incorporation of non-classical amino acids into protein enzymes is a recent hot spot, which can not only improve the catalytic activity of enzymes, but also produce new enzymes that catalyze different reactions, but this method sometimes significantly inhibits the activity of enzymes[10,11].
Polymer modification is also a common method to improve protein function[10,12,13]. Since Abuchowski first conjugated poly (ethylene glycol) to Bovine serum albumin (BSA) in 1977, the covalent modification of polymers has developed rapidly, and various protein-polymer conjugates have been reported, making it an important method to expand the application of proteins[14][15~17]. In this process, the surface grafting methods to achieve covalent modification of polymers are also gradually optimized: from the initial direct coupling of polymers to proteins (grafting-to) to the first attachment of initiators to proteins and the growth of polymers at initiator sites (grafting-from), to the use of polymers as scaffolds and the attachment of multiple proteins on polymers (graft-through). Fig. 1 shows the advantages of different grafting methods and the scope of their adaptation[15,18~22]. Compared with the methods mentioned above, polymer modification has the following advantages: (1) it can improve the physical and chemical properties of proteins in many ways[15,23~25]; (2) it can reduce the immunogenicity of protein drugs and increase the efficacy and safety of drugs[26~28]; (3) It can regulate the self-assembly performance of proteins and form various types of spatial structures as drug delivery carriers and probes for molecular detection. Due to their excellent properties, nowadays, protein-polymer conjugates have been applied in many fields, such as disease therapy, biocatalysis, molecular imaging, drug delivery, and so on[24][29][30][31].
图1 不同接枝方法的原理及其优缺点

Fig. 1 The principles and advantages and disadvantages of different grafting methods.

At present, there are many reviews on protein-polymer conjugates, but these reviews mainly introduce the steps and principles of material synthesis from the perspective of chemical synthesis. Kaupbayeva et al. And Cobo et al. Introduced the application of grafting to, grafting from and grafting through in protein-polymer coupling and their respective advantages and disadvantages from the polymer surface grafting method[32][15]; Xiong et al. And Messina et al. Introduced the application of polymer modified protein in various fields from the perspective of polymer synthesis methods[33][20]; Pelegri-O 'Day et al. And Ekladious et al. Introduced the use of various types of polymers in the modification of proteins[34][24]. The above review gives a comprehensive introduction to the synthesis methods of protein-polymer, but lacks the introduction from the perspective of polymer modification to improve protein function. Improving the function of protein is the goal of various methods, and it is also the key to solve the problems in the application of protein. Only when it is clear how polymer modification can improve protein function can practical problems be solved. Although Kaupbayeva et al. Summarized the application of protein-polymer conjugates from the perspectives of stability and activity of protein-polymer, the review on the function of conjugates is not complete[21]. In this paper, the application examples, existing problems and solutions of protein-polymer conjugates in various fields in recent years are summarized from the functional improvements of polymer modification on protein stability and activity, immunogenicity, solubility and self-assembly, and the development trend of protein-polymer conjugates is predicted.

2 Stability and activity

Protein stability refers to its resistance to extreme environments such as high temperature, extreme pH, etc. Protein function requires a correctly folded spatial structure, but it is easily stimulated by the external environment to change and affect the function of the protein. Studies have shown that polymer modification of proteins can enhance the stability and activity of proteins by adjusting the interaction forces in proteins[1,35~40]. However, this process has been difficult to explain at the molecular level[41~43]. One hypothesis is that the interaction between the polymer and the protein changes the properties of the protein[41,44~48]. For example, Cummings et al. Found that polymers of different charge types have different effects on enzyme activity, in which cationic polymers reduce the probability of enzyme unfolding at very low pH values[41]. They conjectured that the charge interaction between the polymer and the protein is a form of influence on its stability and activity. Based on the experiment of Cummings et al., Munasinghe et al. Further found that polymers with different charge types had different effects on the active center of the enzyme, resulting in different activities of the enzyme[48]. Another hypothesis is that the polymer has a similar function to the molecular chaperone, which can stabilize the protein by stabilizing the structure of the intermediate when the protein unfolds, as shown in Figure 2. Baker et al. Coupled polymers of different types and lengths to serine protease to explore the effect of polymer modification on protein conformation[1]. They found that at pH 1, the spatial structure of the conjugate was minimally changed from the native conformation and retained activity for a long time. They hypothesized that under acidic conditions, the polymer would stabilize the partially unfolded state of the protein and prevent further unfolding and inactivation of the protein. Moreover, polymers with different hydrophilicity and hydrophobicity have different effects on the folding of the intermediate weight back to the native conformation during protein unfolding. Thus, the polymer can help the protein fold back into the correct conformation by mimicking the action of molecular chaperones.
图2 聚合物修饰通过稳定蛋白质展开时中间体的结构而提升蛋白质的稳定性[1]

Fig. 2 Polymer modifications enhance protein stability by stabilizing the structure of the protein’s partially unfolded intermediate[1]

2.1 Stability to temperature and pH

Polymer modification can improve protein stability at high temperatures and pH extremes. Protein drugs are widely used in the field of medicine. However, changes in the environment during storage and transportation often lead to the reduction of their activity and poor efficacy. Human growth hormone (hGH) is a commonly used drug for the treatment of short stature and other diseases, which also has the above problems. In order to improve the stability of hGH, Grigoletto et al. Attached PEG chains to the N-terminal of hGH and Glutamine (Gln) at position 141 mediated by Glutamine amidase, and synthesized PEG-N-terminal-hGH and PEG-Gln141-hGH[49]. The thermal denaturation temperatures of hGH, PEG-Gln141-hGH and PEG-N-hGH were 82, 83.8 and 86 ℃, respectively, measured by circular dichroism spectroscopy, indicating that the polymer could improve the thermal stability of the enzyme. In addition, they found that the conjugate was able to restore its secondary structure after heat denaturation at high temperature, which was beneficial for the protein to recover its specific function after heat denaturation. Of course, in addition to high temperature, polymer modification can also improve stability to pH. Sharma et al. Covalently coupled α-chymotrypsin to a methyl methacrylate polymer via carbodiimide to improve the stability of the enzyme to pH[50]. They placed the conjugate and the natural enzyme in phosphate buffer of pH = 5.7 ~ 8.0, and by measuring the residual activity of the enzyme, they found that the optimum pH range of the conjugate was wider than that of the natural enzyme, and the conjugate had better stability at pH = 6.5 and above. At pH = 5.6, the residual activity of the conjugate was about 80%, while that of the free enzyme was about 40%, indicating that the modification of the polymer could improve the stability of the enzyme to pH.
Polymer modification can simultaneously improve protein stability to temperature and pH. Papain is a highly active proteolytic enzyme, which is widely used in industrial and food processes. Verduzco et al. coupled poly (vinyl-2-pyrrolidone) (PVP) synthesized by Reversible addition-fragmentation chain transfer (RAFT) with papain using the grafting-to method[51]. They studied the catalytic activity of the conjugate with the native enzyme at different pH values and temperatures. Under acidic conditions, with the increase of pH value, the activity of the conjugate was similar to that of the native enzyme. However, at pH = 9.0, the conjugate still retained about 70% of its activity, while the native enzyme had only about 28% of its residual activity. In addition, they found that the conjugate was more active than the native enzyme at different temperatures, and at 70 ℃, the conjugate still had about 60% activity, while the native enzyme had only about 29% activity. The results showed that polymer modification could improve the stability of papain to pH and high temperature.

2.2 Stability to protease hydrolysis

Proteins are susceptible to enzymatic hydrolysis and loss of activity, while polymer modification can mask the relevant reaction sites of proteins or hinder the binding of enzymes to proteins so that proteins are protected from enzymatic hydrolysis. Catalase is a commonly used antioxidant in industry, which can remove toxic substances in bleaching wastewater to achieve the effect of water purification. However, due to the high sensitivity of catalase to protease, its application is greatly limited[52]. Riccardi et al. Synthesized a catalase-PAA conjugate by linking the carboxyl group of Poly (acrylic acid) (PAA) with the amine group on catalase, thereby improving the stability and activity of the enzyme[53]. They used trypsin and chymotrypsin to digest and hydrolyze the conjugate and the native enzyme, and found that the conjugate retained more than 80% of its activity under the action of both enzymes, while the activity of the native enzyme was greatly reduced. Therefore, the stability of catalase modified by PAA against protease hydrolysis was significantly improved. For this phenomenon, they suggest that PAA creates a protective cross-linked network and acts as a physical barrier around the protein, thereby preventing proteases or bacteria from approaching the enzyme embedded in it (Figure 3).
图3 PAA在过氧化氢酶周围形成交联的网络结构限制蛋白酶等大分子的接近,增加对蛋白酶水解的抵抗力[53]

Fig. 3 PAA forms a cross-linked network structure around catalase to restrict the proximity of macromolecules such as protease and increase the resistance to protease hydrolysis[53]

2.3 Stability to chemical denaturant

Polymer coupling can also increase protein stability to chemical denaturants. Cellulase can degrade the β-1,4-glycosidic bond in the main chain of cellulose, so that cellulose can be used as an energy source. However, cellulase is easy to be inactivated in practical application due to the addition of reagents such as dimethyl sulfoxide or dimethylformamide during the hydrolysis of cellulose[54]. Wright et al. Used the RAFT method to graft a variety of polymers onto thermophilic cellulase to improve its stability to chemical denaturants[55]. They tested the residual activity of the enzyme after incubating the various conjugates in a medium consisting of 76 vol% dimethylformamide and 24 vol% pH = 5 buffer for 2 H. The results showed that the polymer-modified enzyme had higher residual activity than the native enzyme. In addition to this, they found that the acrylamide- and N, N-dimethylacryloyl-modified enzyme showed a 50% increase in activity over the native enzyme. This shows that polymer modification can not only improve the stability of the enzyme in extreme environments, but also improve the activity of the enzyme.

2.4 Promotion of enzyme activity

Polymer modification in most cases leads to a decrease in enzyme activity. Therefore, researchers try to improve the stability and activity of polymer modification at the same time, so as to improve the performance of conjugates in all aspects. The work of Cui et al. Successfully achieved this goal[56]. Cysteine (Cys) was introduced into PPase by site-directed mutagenesis. Then 2-methacrylamido glucopyranose (MAG) was synthesized by the substitution reaction of glucosamine and methacryloyl chloride, and PMAG with different molecular weight and ratio was synthesized by RAFT polymerization by controlling the ratio of chain initiator and MAG. Finally, PMAG reacts with pyridine dithioester and introduces a disulfide bond at the terminal position, which is exchanged with the Cys-introduced PPase by disulfide to give PMAG-PPase. The activity of PMAG-PPase with different molecular weights was increased by nearly 30% compared with PPase. In addition, the activity of PPase modified by 8000 Da PMAG was well retained under extreme pH conditions, high salt solution and trypsin. However, the synthesis steps of the polymer are complex, the cost is high, and it is difficult to be widely used. Therefore, in order to simplify this process, Kovaliov et al. Successfully synthesized N- (iso-butoxymethyl) acrylamide (NIBMA) and N- [3- (dimethylamino) propyl] acrylamide (DMAPA) modified Candida Antarctica lipase and Candida albicans lipase with different molecular weights by controlling the illumination time through the photoinduced electron transfer RAFT method proposed by Tucker et al[39][57]. They found that the catalytic activity of the enzyme was significantly improved after the two polymers were coupled. This may be due to the increased solubility and affinity of the hydrophobic substrate in the polymer shell, which increases the effective concentration of the substrate. At the same time, the longer the chain length of DMAPA, the greater the activity of the conjugate, because the tertiary amine part of the polymer increases the enzyme activity by pulling water molecules away from the hydrophobic region of the protein. In addition, the conjugates also showed different degrees of resistance to high temperature.
Polymer-modified proteins can realize enzyme cascade reactions, thereby enhancing the activity of enzymes. When two or more enzymes are immobilized in adjacent spaces, they can catalyze multi-step reactions together, inducing two or more consecutive processes without separation of reaction intermediates, which is called enzyme cascade reaction[58]. The enzyme cascade can reduce the separation and purification steps of the subsequent reaction, so that the upstream reaction product can be directly transferred to the nearby enzyme catalyzing the downstream reaction as a substrate without passing through the equilibrium, thereby increasing the reaction rate[58,59]. Polymer modification is an important method to realize enzyme cascade process, and the formed cascade enzyme has the advantages of adjustable activity, good stability and high biocompatibility[60~62]. Glucose oxidase (GOX) and Horseradish peroxidase (HRP) are often used in combination to detect blood Glucose. Chiang et al. First attached initiators to GOX and HRP respectively, and then mixed the two enzymes attached to the initiators, and carried out Atom-transfer radical-polymerization (ATRP) reaction at the same time to obtain GOX/HRP-Poly (2-hydroxypropyl methacrylate) (PHPMA) conjugate self-assembled into micelle structure, as shown in Figure 4[62]. They regulate the activity of the complex enzyme by regulating the ratio of GOX to HRP. Although both GOX-PHPMA and HRP-PHPMA decreased compared with the native enzyme after coupling with the polymer, the activity of GOX/HRP-PHPMA complex was significantly higher than that of the native enzyme at a specific ratio of GOX to HRP, and the glucose detection speed was faster than that of the commercial glucose analysis kit. Therefore, polymer modification to achieve enzyme cascade can increase the rate of enzymatic reaction, thereby enhancing the activity of the enzyme.
图4 GOX/HRP-PHPMA偶联物的合成原理及其实现复合酶级联反应,增加反应效率的过程[62]

Fig. 4 The synthesis principle of GOX/HRP-PHPMA conjugates and the process of realizing complex enzyme cascade reaction to increase reaction efficiency[62]

2.5 Regulation of enzyme activity

In the process of using enzymes, it is sometimes necessary to adjust their activity so that they can carry out the required catalytic reaction at the right place and time to avoid the occurrence of side reactions or slow down the "aging" process of enzymes. The polymer can regulate the activity of the enzyme in two ways: first, the polymer can be reversibly linked to the enzyme, and the structure of the enzyme is affected by the coupling and shedding of the polymer, thereby regulating the activity of the enzyme[63]; Secondly, stimuli-responsive polymers can be used to regulate enzyme activity by responding to external environmental conditions[64,65]. Wang et al. Introduced Cys to PPase by site-directed mutagenesis, and coupled the thiol group with poly (2-hydroxyethyl methacrylate) (PHEMA) functionalized with pyridine disulfide to form PPase-PHEMA[63]. PPase activity was almost completely lost after PHEMA coupling, but was restored to a level comparable to that before coupling after reduction of the disulfide bond between PHEMA and PPase with 8 mmol/L dithiothreitol. Li et al. Used the photoelectron transfer RAFT method to couple the thermosensitive polymer poly (N-isopropylacrylamide) (PNIPAAM) to the Cys far away from the active center of PPase by site-directed mutagenesis to obtain PPase-PNIPAAM[64]. The catalytic activity of the conjugate has a clear difference between the two sides of the ambient temperature at the phase transition temperature of PNIPAAM. It is speculated that the principle of thermal response of enzyme activity may be that PNIPAAM is in a stretched state below the phase transition temperature, shielding the active center of the enzyme, while the polymer chain is compressed and folded above the phase transition temperature, exposing the active center.

3 Immunogenicity

Immunogenicity is one of the major factors limiting the bioavailability of protein drugs in vivo. Protein immunogenicity means that the immune system in vivo will produce an immune response to foreign proteins and eliminate them, mainly triggered by the binding of immune cells to antigenic determinants on the surface of proteins[34]. Many studies have shown that polymer coupling can reduce the immunogenicity of proteins, and there are two hypotheses about the specific mechanism: (1) the polymer hinders the specific recognition process between proteins and immune cells[34,66,67][34,68]; (2) The polymer shields the antigenic groups on the surface of the protein, making it "invisible" to antibodies[69].
Polymers on the surface of protein-polymer conjugates can hinder the specific recognition process between proteins and immune cells, thus reducing the immunogenicity of proteins. Viral capsid proteins usually have strong immunogenicity, which is a common material to study the reduction of protein immunogenicity by polymer coupling. Steinmetz et al. Coupled 1000 Da and 2000 Da PEG chains on the capsid surface of Cowpea mosaic virus (CPMV), respectively, and achieved "visualization" by dye labeling, combined with flow cytometry analysis, to study the effect of polymers with different chain lengths on the interaction between virus and host cells without affecting the biological activity of CPMV[70]. They observed that the binding and uptake rates of CPMV by host cells were reduced to varying degrees after PEG-conjugated viruses of two lengths, and PEG2000 was significantly better than PEG1000. The longer the chain length, the greater the steric hindrance, indicating that polymer coupling can hinder the interaction between protein and cell surface through steric hindrance. In addition, Mok et al demonstrated that PEGylated Adenovirus (AD) can reduce the interaction between AD and immune cells, thereby reducing the innate immune response[71]. They observed that the level of Interleukin-6 secreted by macrophages co-cultured with AD-PEG was significantly lower than that of AD, and the uptake of AD-PEG by macrophages was reduced. In addition, the serum IL-6 level in AD-PEG group was also significantly lower than that in AD group after injection of AD-PEG and AD respectively. Therefore, polymer coupling can hinder the uptake of proteins by antigen presenting cells, thereby reducing the production of immunostimulatory factors and weakening the body's innate immune response to proteins. On the basis of the work of Mok et al., Eto et al. Further explored the change of anti-AD antibody level in rat serum after PEG modification of AD[72]. They found that the level of anti-AD antibody in serum decreased significantly after PEG modification, and the higher the modification rate, the higher the degree of decrease. To sum up, polymer coupling can hinder the recognition process between proteins and immune cells, reduce the production of immune response, and reduce the production of corresponding immunostimulatory factors and antibodies.
The polymer can shield the antigen group on the surface of the protein, reduce the affinity with the antibody, and reduce the neutralization reaction with the antibody[73,74]. Wu et al. Conjugated uricase with a block copolymer formed by PEG and Polysialic acid (PSA), and found that the affinity of the conjugate with uricase-specific antibody decreased by enzyme-linked immunosorbent assay[75]. They used transmission electron microscopy to observe the shape and state of uricase-PEG-PSA conjugate nanoparticles in solution, and found that the nanoparticles would aggregate into microspheres in solution, and a spherical hydration shell with a larger particle size appeared. The hydration shell formed by the surface polymer may hinder its binding to the antibody through the steric barrier effect, thereby reducing the avidity of the antibody. Lee et al. Conjugated different types of polymers to Qβ phage and found that the binding rate of Qβ to antibody decreased after polymer conjugation[76]. They speculated that different types of polymers form shells of different thickness on the surface of the viral capsid, hindering the binding of antibodies. In addition, there are different interactions between polymers and proteins, which affect the binding process with antibodies.
In addition to the above two mainstream mechanisms, there are also some other hypotheses. For example, it is known that polymer-conjugated proteins can form nanoparticles with different shapes, and the different shapes of nanoparticles have significant differences in their interaction with cells and distribution in vivo, thus affecting the immunogenicity of proteins in vivo[77~79]. Therefore, polymer coupling can reduce the immunogenicity of protein in many ways, prolong the half-life of protein drugs in vivo, and improve their efficacy and safety.

4 Solubility

Solubility is a basic property of protein, which is of great significance to the realization of protein function. Enzyme-catalyzed reactions in anhydrous ionic liquids or organic solvents can effectively avoid hydrolysis side reactions and increase the solubility of non-polar substrates, which is conducive to the improvement of reaction efficiency and the separation and recovery of enzymes[80~82]. However, the low stability and low solubility of enzyme molecules in organic solvents lead to the low activity of enzyme molecules, which limits the application of enzymes in organic solvents[82~84]. The modification of polymers can increase the solubility of proteins in organic solvents and anhydrous ionic liquids, and broaden the application range of enzymes[85-87]. In addition, modification of solubility by polymers is an important purification method in protein purification[88]. In industrial applications, the improved solubility of the protein-polymer pair also enables the enzyme to be reused, thereby reducing production costs.
Protein-polymer conjugates can regulate the solubility of proteins by adjusting the type and chain length of the polymer. Baker et al. Used the ATRP method to synthesize lysozyme-polymer conjugates with high grafting density and different polymer chain lengths[88]. They chose amphiphilic poly (carboxybetaine methacrylate) (PCBMA) and neutral poly (oligo (ethylene glycol) methacrylate) (POEGMA) to couple with Lysozyme (Lyz), respectively, to study the effect of polymers on protein solubility. At pH = 7.0, Lyz precipitates at about 60% of the saturated concentration of ammonium sulfate, while the Lyz-polymer conjugate is soluble in saturated ammonium sulfate solution. They speculated that the amphiphilic polymer could prevent the hydration layer around the protein from being consumed, or prevent the protein from precipitating when the hydration layer is depleted. Therefore, they tested the solubility of proteins in ammonium sulfate solution when modified by amphiphilic polymers of different lengths. The results showed that the higher the length of the amphiphilic polymer, the higher the saturation of ammonium sulfate during salting out. Inspired by the above work, it is conjectured that the purification process of protein-polymer conjugates can be simplified by designing polymers to regulate the solubility of proteins.
The coupling of the polymer to the protein can also enhance the solubility of the protein in the organic phase. Takahashi et al. Coupled PEG with the amino group of HRP, and the modified enzyme was easily soluble in benzene solution and retained 21% of the activity of the native enzyme, which was the first report on the activity and solubility of the enzyme in organic solvents[89]. Later, Inada et al. Also found that the enzyme could be soluble and active in organic solvents by chemical modification with PEG[90]. Coupling the polymer to the enzyme to improve the solubility of the enzyme in organic solvents can expand the application range of the enzyme[91].
The coupling of stimulus-responsive polymer and protein can regulate the solubility of protein in different environments, so that the protein-polymer conjugate has environmental responsiveness. Yoshihara et al. Synthesized a temperature-responsive HSA-PNIPAAM conjugate by introducing a chain transfer agent into BSA using the "grafting from" method, in which BSA can specifically adsorb uremic toxin-Indoxyl sulfate (IS)[92]. Using the thermal precipitation effect of the conjugate, the conjugate can be recovered above the minimum critical temperature, as shown in fig. 5. The conjugate is expected to be used in dialysis therapy to recover albumin from dialysate and reduce medical costs. Steiert et al. Prepared an acid-responsive nanoparticle[93]. They incorporated vinyl ether into the main chain of PEG, and then modified the conjugate to the surface of cytochrome C to form pH-responsive protein nanoparticles. The nanoparticle is stable in a neutral environment, and under acidic conditions, the vinyl ether in the conjugate is degraded, most of the PEG material is cleaved, and only very small PEG fragments remain on the protein surface. In this way, the protein regains its native hydrophilic solubility, and individual hydrophobic protein assemblies are disassembled. They demonstrated the nontoxicity of the conjugate to HeLa cells and its stability at pH = 7.4, and then utilized the nanosystem to encapsulate fluorescently labeled dextran and observed the release of dextran under acidic conditions. From these characteristics, it can be inferred that the protein-stimuli-responsive polymer can be used as a drug carrier to selectively kill tumor cells by releasing the drug through the dissolution of the conjugate in a weak acidic tumor environment.
图5 温度响应性BSA-PNIPAAM偶联物的合成,偶联物吸附IS,并通过热沉淀回收IS[92]

Fig. 5 Synthesis of the thermally responsive polymer-protein conjugate system. Then the conjugate capture IS. Finally, the captured IS is recovered by thermal precipitation[92]

5 Self-assembly

The self-assembly of proteins into specific three-dimensional structures depends on the order of amino acids, but this property can be regulated by internal interactions and external stimuli. Polymer modification can change the properties of protein surface and regulate its self-assembly process, thus controlling the formation of specific spatial structure of conjugates, which is called polymerization-induced self-assembly[94~96]. Hydrophobic polymers form amphiphilic molecules when coupled to hydrophilic proteins[78,97,98]. Amphiphilic molecules can self-assemble in aqueous medium, for example, phospholipid molecules can form spherical closed molecules, micelles, rod-like structures in water[98]. Amphiphilic protein-polymer conjugates can self-assemble into many higher-order structures, such as micelles, vesicles, bilayers, sheets, etc[99~101]. Nanoparticles formed by self-assembling protein-polymer conjugates can be used as carriers to encapsulate drugs, enzymes, fluorescent molecules or other hydrophobic substances, thus realizing the functional integration of proteins, polymers and encapsulated substances and the construction of multifunctional systems[30,62,78,95]. The coupling of functional polymers and proteins can also expand and improve the functions of proteins[102~104]. The construction of self-assembled protein-polymer nanostructures has unique applications in drug delivery, molecular detection, and other fields[30,105].

5.1 Drug delivery

Polymer-coupled proteins can self-assemble into specific spatial structures to load drugs. Albumin is easy to accumulate in tumor tissue and be taken up by tumor cells, so it is often used as a targeting carrier of anti-tumor drugs[106,107]. As shown in fig. 6, Liu et al. Linked hydrophobic poly (ε-caprolactone) (PCL) with hydrophilic BSA through maleimide-thiol reaction, and prepared degradable BSA-PCL vesicles through amphiphilic self-assembly of the material[99]. The hydrophobic core of the vesicle can be loaded with the anti-tumor drug doxorubicin, and the surface can be conjugated with antibodies to further improve the targeting. In cell and animal experiments, the in vitro anti-tumor properties of the system are significantly enhanced relative to doxorubicin. In addition, the system has high selectivity and biodegradability, and reduces the in vivo toxicity of doxorubicin[108]. On the basis of the above, many studies have further analyzed the performance of BSA-polymer conjugates[107]. The coupling of the polymer can enhance the absorption of BSA by tumor cells. Piperazine derivatives are chemical permeation enhancers that alter the integrity of tight junctions between epithelial cells and increase permeation through the paracellular pathway. Cummings et al. Used ATRP method to grow phenylpiperazine acrylamide monomer on the surface of BSA, and prepared BSA-polymer conjugates containing phenylpiperazine[109]. At non-cytotoxic doses, the conjugate increased the permeability of Caco-2 monolayer by about 30-fold compared with BSA, which mimics the absorption of small intestine, and has potential prospects for oral drug delivery.
图6 表面修饰配体的负载阿霉素的BSA-PCL囊泡的合成及其增加对肿瘤组织的靶向性的过程[99]

Fig. 6 Synthesis of doxorubicin-loaded BSA-PCL vesicles with surface-modified ligands and its increased targeting to tumor tissue [99]

Stimulus-responsive polymer-coupled protein-loaded drugs can control the time and site of drug release according to the change of environment, and enhance the selectivity of drugs[110]. Vanparijs et al. Grown [ (2,2-dimethyl-1,3-dioxolane) methyl] acrylamide (DMDOMA) on lysine residues of BSA by RAFT method to form acid-soluble BSA-PD MDOMA conjugate[111]. They encapsulated immunostimulatory molecule CL075 in the hydrophobic inner core of BSA-PDMDOMA, so that the nanoparticles were dissolved and activated in the acidic environment of the endosome after uptake by dendritic cells, and enhanced the immune response to tumors and intracellular pathogens. Inspired by the above work, Viana et al. Used ATRP to simultaneously grow temperature-sensitive polymers N-vinylcaprolactam and N, N-dimethylaminoethyl methacrylate on lysine residues of BSA to prepare BSA-block polymer conjugates[106]. By controlling the ratio of the two thermosensitive polymers, they can adjust the phase transition temperature of the conjugate to 40 ℃, which has a potential targeting effect on tumor tissues above physiological temperature. However, they have no relevant animal experiments to prove that the material can achieve tumor tissue aggregation.
Some proteins themselves can be used as carriers, and after self-assembly, they form hollow spaces inside, which can load drugs, such as viral capsid, ferritin, chaperone and so on. This kind of protein is named protein cage, and some researchers have made a good summary of the related research[112,113]. Due to the defects of the protein application process mentioned above, we can imagine that coupling polymers on the surface or inside of the protein cage can improve its corresponding properties, such as surface modification of PEG to reduce its immunogenicity. Many studies have modified protein cages from different perspectives to increase the possibility of their clinical application as drug carriers. Nussbaumer and his group coupled the dendrimer polyacrylamide to the pore size of the chaperone Thermosome (THS) through a bisarylamine linker, and used the charge effect to load the positively charged polymer with negatively charged siRNA[114]. The vector system can protect the siRNA from being degraded and can play a better gene silencing effect on U87 tumor cells. However, the use of THS in drug delivery vehicles is relatively rare, and its safety and efficacy in clinical studies remain to be investigated. Viral capsid is a commonly used vector for gene therapy, in which AD is the focus of research. However, the application of AD vector in gene therapy is limited by some problems, such as easy uptake and inactivation by immune cells during intravenous injection, toxicity caused by interaction with platelets and erythrocytes, hepatotoxicity caused by accumulation in the liver, and low expression of AD receptor on the surface of tumor cells, which leads to low gene transduction efficiency[115,116]. In order to solve these problems, Kim et al. First attached Arginine-grafted bioreducible polymer (ABP) to the surface of AD through charge interaction, which improved the transduction efficiency of AD, reduced the immunogenicity and erythrotoxicity. However, the particle size of the vector system was as high as 500 nm, and it was prone to aggregation, so it could not be administered by intravenous injection[117]. They therefore further developed an AD-ABP system chemically coupled through a disulfide bond. The size of the conjugate is less than 150 nm, which is suitable for intravenous administration, and the surface is positively charged, which prevents the aggregation of the conjugate and solves the above problems[115]. Thambi et al. And Sun et al. Also reviewed the corresponding studies on the coupling of AD with different types of polymers[116][118]. Apoferritin is also a protein shell of natural origin, which dissociates 24 subunits at pH = 2 and restores the shell structure at neutral pH, and is a potential pH-responsive drug delivery carrier. Luo et al. Modified the polysaccharide, Hyaluronic acid (HA), on the surface of apoferritin by EDC-NHS method, and used the targeting effect of HA on the highly expressed CD44 receptor on the surface of tumor cells to achieve selective drug delivery[119]. They encapsulated daunomycin and negatively charged macromolecule polyaspartic acid in the protein cage, and the drug was stably encapsulated in the protein cage through the attraction between polyaspartic acid and positively charged daunomycin. The drug delivery system constructed by them has a fast release rate at low pH, a good response behavior to the acidic tumor microenvironment, and a dual-targeted killing effect on lung cancer cell models due to the binding of HA and CD44 receptors.

5.2 Molecular imaging

With the development of biopharmaceuticals in recent years, especially the increasing proportion of protein drugs in the drug market share year by year, researchers hope to have an efficient protein labeling technology to better understand the dynamic distribution of protein drugs in the body. Among all kinds of labeling methods, fluorescent polymer-based labeling technology has attracted the attention of researchers in recent years because of its excellent performance. Its advantages include smaller fluorescent polymer chain size compared to inorganic or organic nanoparticles, brighter brightness compared to organic dyes, and significantly enhanced resistance to photobleaching[120,121]. In addition, due to the biocompatibility, water solubility and the ability to modify multifunctional groups on the surface of polymers, researchers can use bioorthogonal reactions to achieve protein-specific fluorescent labeling on the surface of living cells, thus realizing applications in cell imaging and other fields[122]. Duret et al. Synthesized a block copolymer of 4-acryloylmorpholine and N-acryloxysuccinimide (NAS) by RAFT method[120]. They successfully labeled streptavidin by multi-site binding of an amino-modified fluorescent dye on the side chain of the N-hydroxysuccinimidyl activated ester of NAS in the polymer backbone, followed by covalent binding of the activated ester at the polymer terminus to primary amines on multiple lysine residues on the protein. Finally, the material was combined with biotin-labeled anti-CD40 antibody by bioaffinity reaction. After co-incubation with dendritic cells, flow cytometry showed that dendritic cells had strong fluorescence brightness. Although the material has good performance, the synthesis steps of the material are complicated and the cost is high, which limits its popularization and application. Some researchers have also directly linked fluorescent polymers to antibody molecules to obtain antibody-polymer-dye conjugates with enhanced fluorescence signals[123~125]. Herceptin is an anti-tumor monoclonal antibody drug, which can treat breast cancer, ovarian cancer, gastric cancer and other diseases. Zhang et al. Combined ATRP initiator on Herceptin, and simultaneously grew POEGMA and rhodamine-modified POEGMA on this site to obtain site-specific antibody-polymer-dye conjugate[125]. They obtained three types of Herceptin-POEGMA-rhodamine conjugates by adjusting the ratio of dye-modified monomer and antibody during ATRP. Compared with the rhodamine dye directly coupled with Herceptin disulfide bond, the signal intensity of antigen detection was significantly enhanced, and the specificity of Herceptin antibody binding to antigen was not changed. This study combines the targeting and therapeutic properties of antibodies and the imaging properties of fluorescent polymers, which helps to achieve the integration of diagnosis and treatment, and is one of the key development directions of modern medicine.
The specific spatial structure formed by the self-assembled protein-polymer can also load dye molecules, and the dye molecules can be released by using the structural change of the responsive polymer in a specific environment to realize the corresponding imaging process. poly (2- (diisopropylamino) ethyl methacrylate) (PDPA) is a pH-responsive polymer with an isoelectric point of about 6.5. When the pH is lower than the isoelectric point, the tertiary amino group of PDPA is protonated and hydrated to form a hydrophilic polymer. Li et al. Linked the maleimide-functionalized ATRP initiator to the thiol group on the Cys of Human serum albumin (HSA), and the DPA monomer grew on this site, and the conjugate self-assembled to form HSA-PDPA micelles of various shapes[30]. They obtained HSA-PDPA spherical micelles by controlling the critical micelle concentration, and incorporated Indocyanine green (ICG) into the core of the micelles to form pH-responsive fluorescent nanoprobes. At blood pH, quenching of fluorescent molecules occurs due to aggregation within the micelle. At the pH of the tumor site, the nanoprobe dissociates into positively charged monomers, resulting in enhanced fluorescence and uptake of the monomers by tumor cells, as shown in fig. 7. They proved that the nanoprobe had excellent tumor fluorescence imaging performance after intravenous injection through corresponding mouse experiments, which provided the possibility of tumor-specific imaging.
图7 HSA-PDPA/ICG(HDI)纳米探针的合成、pH响应性及肿瘤组织的特异性成像[30]

Fig. 7 Synthesis, pH response and tumor specific imaging of HSA-PDPA/ICG (HDI) nanoprobes[30]

6 Conclusion and Prospect

In recent years, due to the rapid development of "click chemistry", "polymerization mechanism" and "surface grafting modification", people can quickly synthesize a variety of protein-polymer conjugates with unique functions. Scientists have synthesized a large number of protein-polymer conjugates by grafting various polymers on the surface of proteins. Through a series of characterization methods, protein-polymer conjugates with different functions were screened out and applied in various fields.
In the pharmaceutical field, more than a dozen protein-coupled polymer drugs have entered the market, such as polymer-coupled antihemophilic factor and hGH, which have been approved by FDA in recent years[126~129]. In addition, a number of polymer-conjugated protein drugs are undergoing phase I, II, and III clinical trials[130]. Polymer-conjugated IL-2, arginine deaminase, and antigen-binding domain against CD40 are in phase II and phase III clinical trials, respectively, and are expected to have good results[130]. In addition, protein-polymer conjugates also have important applications in the fields of nanomaterials synthesis, molecular separation and catalysis[131]. Sharma et al. Reported BSA-polymer conjugate as an anhydrous solvent for drying solutes of different size and surface chemistry[132]; Nanotubes Formed by Cyclic Peptide-Polymer Conjugates can Mimic Carrier Proteins for Small Molecule Transport[133,134]; Polymer coupling can enhance the stability, activity and recyclability of enzymes to reduce the cost of enzymes[26,28,55].
Although protein-polymer has good application prospects in various fields, a series of problems emerging in the process have undoubtedly undermined the confidence of researchers. The uncertainty of the length, density and modification site of the polymer can easily lead to the reduction or even loss of the activity of the protein, or the generation of heterogeneous mixtures to destabilize its activity[44,135~137]. But in the process of exploration, scientists have also found a series of ways to solve these problems, as shown in Figure 8: (1) Reversible connection: the polymer and protein are connected by reversible covalent bonds, and the polymer can be released from the protein without trace in a specific environment or after a period of time[138~140]; (2) specific site grafting: the polymer is modified at a specific position on the protein by using a chemical linker or a specific catalytic reaction of an enzyme, so that the modification site is controlled to be far away from the active center, and the influence of the process on the activity of the enzyme is reduced[131,135,141]; (3) By means of genetic engineering, the grafting site far away from the active center of the protein is created by editing[142]. In addition to the above common methods, Yang et al. Proposed that the structure of chain transfer agent is also an important factor affecting the activity of protein in controlled radical polymerization, and the appropriate structure can make the polymer modification not affect its biological activity even near the active center of protein[65].
图8 避免蛋白质-聚合物偶联物活性降低的措施:A可逆连接;B特定位点修饰;C 基因编辑

Fig. 8 Measures to avoid decreased activity of protein- polymer conjugates: A reversible linkage; B site-specific modifications; C gene editing

Many studies have reported that polymers that are difficult to degrade or have strong immunogenicity in the human body can trigger the body's immune response and produce specific antibodies[2,24,143]. This can lead to severe allergic reactions to polymer-modified protein drugs[2,144,145]. As a result, scientists and drug approval agencies are beginning to rethink the safety of polymers. Although more than a dozen PEGylated proteins were approved by FDA in the early stage, with the improvement of drug approval process, many polymer-modified protein drugs failed in clinical trials.It has raised questions about the safety of polymer-modified protein drugs, but it has also inspired researchers to find a new generation of polymers to avoid this side effect[23]. Researchers have begun to use human endogenous substances or degradable polymers with low immunogenicity to replace PEG, as shown in Table 1, which introduces various PEG alternatives currently under study.
表1 目前正在使用和开发的PEG替代品的例子,PG,聚甘油; PAOx,聚(2-烷基-2- 唑啉)

Table 1 Examples of current alternatives to PEG in use and development. PG, poly (glycerol); PAOx, poly (2-oxazoline)s

Examples of alternatives to PEG currently in use and development
Biodegradable PSA[146]、PCL[99]、HA[119]
Non-Biodegradable PHPMA[147]、PVP[148]、PAOx[149]
Branched and Comb PG[150]
Protein-polymer research has also changed in the course of decades of exploration. At first, researchers mainly used polymers to change the properties of proteins, but many recent studies have combined protein-polymer conjugates into a system that fully utilizes the functions of both polymers and proteins. In addition, there are also many studies on the combination of conjugates and other functional molecules to form copolymers, which self-assemble into specific spatial structures to wrap other molecules, forming nanoparticles with a variety of special properties. Recent studies have provided a new way of thinking: we can not only use polymers to regulate the properties of proteins, but also combine the functions of polymers themselves to expand the applications of proteins. We suspect that building similar systems may be one of the mainstream directions for polymer-modified protein applications in the future.
In a word, we hope that this article can inspire researchers to design intelligent responsive protein-polymer conjugates from a functional point of view, so that they can play an ideal role.
[1]
Baker S L, Munasinghe A, Murata H, Lin P, Matyjaszewski K, Colina C M, Russell A J. Biomacromolecules, 2018, 19 (9): 3798.

[2]
Liu S J, Jiang S Y. Nano Today, 2016, 11 (3): 285.

[3]
Ingenbosch K N, Vieyto-Nuñez J C, Ruiz-Blanco Y B, Mayer C, Hoffmann-Jacobsen K, Sanchez-Garcia E. J. Org. Chem., 2022, 87 (3): 1669.

[4]
Silva C, Martins M, Jing S, Fu J J, Cavaco-Paulo A. Crit. Rev. Biotechnol., 2018, 38 (3): 335.

[5]
Bosio V E, Islan G A, Martinez Y N, Duran N, Castro G R. Crit. Rev. Biotechnol., 2016, 36 (3): 447.

[6]
Kujawa J, Glodek M, Li G Q, Al-Gharabli S, Knozowska K, Kujawski W. Sci. Total Environ., 2021, 801: 149647.

[7]
Russell A J, Baker S L, Colina C M, Figg C A, Kaar J L, Matyjaszewski K, Simakova A, Sumerlin B S. AIChE. J., 2018, 64 (9): 3230.

[8]
Ge J, Lei J D, Zare R N. Nat. Nanotechnol., 2012, 7 (7): 428.

[9]
Khan S, Babadaei M M N, Hasan A, Edis Z, Attar F, Siddique R, Bai Q, Sharifi M, Falahati M. J. Adv. Res., 2021, 33: 227.

[10]
Pagar A D, Patil M D, Flood D T, Yoo T H, Dawson P E, Yun H. Chem. Rev., 2021, 121 (10): 6173.

[11]
Drienovská I, Roelfes G. Nat. Catal., 2020, 3 (3): 193.

[12]
Pessatti T B, Terenzi H, Bertoldo J B. Catalysts, 2021, 11 (12): 1466.

[13]
Shadish J A, DeForest C A. Matter, 2020, 2 (1): 50.

[14]
Abuchowski A, van Es T, Palczuk N C, Davis F F. J. Biol. Chem., 1977, 252 (11): 3578.

[15]
Cobo I, Li M, Sumerlin B S, Perrier S. Nat. Mater., 2015, 14 (2): 143.

[16]
Schulz J D, Patt M, Basler S, Kries H, Hilvert D, Gauthier M A, Leroux J C. Adv. Mater., 2016, 28 (7): 1455.

[17]
Murata H, Carmali S, Baker S L, Matyjaszewski K, Russell A J. Nat. Commun., 2018, 9 (1): 845.

[18]
Liu X Y, Gao W P. Angewandte Chemie, International Edition, 2021, 60 (20): 11024.

[19]
Cao L M, Shi X J, Cui Y C, Yang W K, Chen G J, Yuan L, Chen H. Polym. Chem., 2016, 7 (32): 5139.

[20]
Messina M S, Messina K M M, Bhattacharya A, Montgomery H R, Maynard H D. Prog. Polym. Sci., 2020, 100: 101186.

[21]
Wright T A, Page R C, Konkolewicz D. Polym. Chem., 2019, 10 (4): 434.

[22]
Giri P, Pagar A D, Patil M D, Yun H. Biotechnol. Adv., 2021, 53: 107868.

[23]
Duncan R. J. Drug Target., 2017, 25 (9-10): 759.

[24]
Ekladious I, Colson Y L, Grinstaff M W. Nat. Rev. Drug Discov., 2019, 18 (4): 273.

[25]
Thakor P, Bhavana V, Sharma R, Srivastava S, Singh S B, Mehra N K. Drug Discov. Today, 2020, 25 (9): 1718.

[26]
Mukherjee I, Sinha S K, Datta S, De P. Biomacromolecules, 2018, 19 (6): 2286.

[27]
Huynh V, Ifraimov N, Wylie R G. Polymers, 2021, 13 (16): 2772.

[28]
MacKenzie K J, Francis M B. J. Am. Chem. Soc., 2013, 135 (1): 293.

[29]
Rahman M S, Brown J, Murphy R, Carnes S, Carey B, Averick S, Konkolewicz D, Page R C. Biomacromolecules, 2021, 22 (2): 309.

[30]
Li P Y, Sun M M, Xu Z K, Liu X Y, Zhao W G, Gao W P. Biomacromolecules, 2018, 19 (11): 4472.

[31]
Kim J S, Sirois A R, Vazquez Cegla A J, Jumai'an E, Murata N, Buck M E, Moore S J. Bioconjugate Chem., 2019, 30 (4): 1220.

[32]
Kaupbayeva B, Russell A J. Prog. Polym. Sci., 2020, 101: 101194.

[33]
Xiong Q Y, Zhang X Y, Wei W F, Wei G, Su Z Q. Polym. Chem., 2020, 11 (10): 1673.

[34]
Pelegri-O'Day E M, Lin E W, Maynard H D. J. Am. Chem. Soc., 2014, 136 (41): 14323.

[35]
Choi J M, Han S S, Kim H S. Biotechnol. Adv., 2015, 33 (7): 1443.

[36]
Averick S, Simakova A, Park S, Konkolewicz D, Magenau A J D, Mehl R A, Matyjaszewski K. ACS Macro Lett., 2012, 1 (1): 6.

[37]
Tian K Y, Tai K E, Chua B J W, Li Z. Bioresour. Technol., 2017, 245 (Pt B): 1491.

[38]
Zaak H, Siar E H, Kornecki J F, Fernandez-Lopez L, Pedrero S G, Virgen-Ortíz J J, Fernandez-Lafuente R. Process. Biochem., 2017, 56: 117.

[39]
Kovaliov M, Allegrezza M L, Richter B, Konkolewicz D, Averick S. Polymer, 2018, 137: 338.

[40]
Milczek E M. Chem. Rev., 2018, 118 (1): 119.

[41]
Cummings C S, Campbell A S, Baker S L, Carmali S, Murata H, Russell A J. Biomacromolecules, 2017, 18 (2): 576.

[42]
Cummings C, Murata H, Koepsel R, Russell A J. Biomacromolecules, 2014, 15 (3): 763.

[43]
Campbell A S, Murata H, Carmali S, Matyjaszewski K, Islam M F, Russell A J. Biosens. Bioelectron., 2016, 86: 446.

[44]
Lucius M, Falatach R, McGlone C, Makaroff K, Danielson A, Williams C, Nix J C, Konkolewicz D, Page R C, Berberich J A. Biomacromolecules, 2016, 17 (3): 1123.

[45]
Rodríguez-Martínez J A, Solá R J, Castillo B, Cintrón-Colón H R, Rivera-Rivera I, Barletta G, Griebenow K. Biotechnol. Bioeng., 2008, 101 (6): 1142.

[46]
Yang C, Lu D N, Liu Z. Biochemistry, 2011, 50 (13): 2585.

[47]
Farhadian S, Shareghi B, Saboury A A, Babaheydari A K, Raisi F, Heidari E. Int. J. Biol. Macromol., 2016, 92: 523.

[48]
Munasinghe A, Baker S L, Lin P, Russell A J, Colina C M. Soft Matter, 2020, 16 (2): 456.

[49]
Grigoletto A, Mero A, Zanusso I, Schiavon O, Pasut G. Macromol. Biosci., 2016, 16 (1): 50.

[50]
Sharma S, Kaur P, Jain A, Rajeswari M R, Gupta M N. Biomacromolecules, 2003, 4 (2): 330.

[51]
Verduzco L E, García-Pérez A L, Guerrero-Santos R, Ledezma-Pérez A, Romero-García J, Torres-Lubián J R. Can. J. Chem., 2021, 99 (1): 10.

[52]
Polizzi K M, Bommarius A S, Broering J M, Chaparro-Riggers J F. Curr. Opin. Chem. Biol., 2007, 11 (2): 220.

[53]
Riccardi C M, Cole K S, Benson K R, Ward J R, Bassett K M, Zhang Y R, Zore O V, Stromer B, Kasi R M, Kumar C V. Bioconjugate Chem., 2014, 25 (8): 1501.

[54]
Sen S, Martin J D, Argyropoulos D S. ACS Sustainable Chem. Eng., 2013, 1 (8): 858.

[55]
Wright T A, Dougherty M L, Schmitz B, Burridge K M, Makaroff K, Stewart J M, Fischesser H D, Shepherd J T, Berberich J A, Konkolewicz D, Page R C. Bioconjugate Chem., 2017, 28 (10): 2638.

[56]
Cui Y C, Li Z H, Wang L, Liu F, Yuan Y Q, Wang H W, Xue L L, Pan J J, Chen G J, Chen H, Yuan L. J. Mater. Chem. B, 2016, 4 (32): 5437.

[57]
Tucker B S, Coughlin M L, Figg C A, Sumerlin B S. ACS Macro Lett., 2017, 6 (4): 452.

[58]
Hwang E T, Lee S. ACS Catal., 2019, 9 (5): 4402.

[59]
Benítez-Mateos A I, Roura Padrosa D, Paradisi F. Nat. Chem., 2022, 14 (5): 489.

[60]
Vaidya B K, Ingavle G C, Ponrathnam S, Kulkarni B D, Nene S N. Bioresour. Technol., 2008, 99 (9): 3623.

[61]
Zhang Y, Wang B-C, Wang P, Ju X-J, Zhang M-J, Xie R, Liu Z, Wang W, Chu L-Y. React. Chem. Eng., 2022, 7 (2): 275.

[62]
Chiang C W, Liu X, Sun J, Guo J, Tao L, Gao W. Nano Lett., 2020, 20 (2): 1383.

[63]
Wang L, Yuan L, Wang H W, Liu X L, Li X M, Chen H. Bioconjugate Chem., 2014, 25 (7): 1252.

[64]
Li X, Wang L, Chen G J, Haddleton D M, Chen H. Chem. Commun., 2014, 50 (49): 6506.

[65]
Yang W K, Zhu L J, Cui Y C, Wang H W, Wang Y W, Yuan L, Chen H. ACS Appl. Mater. Interfaces, 2016, 8 (25): 15967.

[66]
Sheremet'ev S V, Lonshakov D V, Belosludtseva E M, Borisova O V, Sidorova A V, Kalinskii A V. Pharm. Chem. J., 2021, 55 (7): 698.

[67]
Zhang X W, Wang H, Ma Z G, Wu B J. Expert Opin. Drug Metab. Toxicol., 2014, 10 (12): 1691.

[68]
Lee K L, Shukla S, Wu M Z, Ayat N R, El Sanadi C E, Wen A M, Edelbrock J F, Pokorski J K, Commandeur U, Dubyak G R, Steinmetz N F. Acta Biomater., 2015, 19: 166.

[69]
Harris J M, Chess R B. Nat. Rev. Drug Discov., 2003, 2 (3): 214.

[70]
Steinmetz N F, Manchester M. Biomacromolecules, 2009, 10 (4): 784.

[71]
Mok H, Palmer D J, Ng P, Barry M A. Mol. Ther., 2005, 11 (1): 66.

[72]
Eto Y, Yoshioka Y, Ishida T, Yao X L, Morishige T, Narimatsu S, Mizuguchi H, Mukai Y, Okada N, Kiwada H, Nakagawa S. Biol. Pharm. Bull., 2010, 33 (9): 1540.

[73]
Church D C, Davis E, Caparco A A, Takiguchi L, Chung Y H, Steinmetz N F, Pokorski J K. Cell Rep. Phys. Sci., 2022, 3 (10): 101067.

[74]
Crooke S N, Zheng J K, Ganewatta M S, Guldberg S M, Reineke T M, Finn M G. ACS Appl. Bio Mater., 2019, 2 (1): 93.

[75]
Wu J R, Lu S Z, Zheng Z Y, Zhu L, Zhan X B. Prep. Biochem. Biotechnol., 2016, 46 (8): 788.

[76]
Lee P W, Isarov S A, Wallat J D, Molugu S K, Shukla S, Sun J E P, Zhang J, Zheng Y, Lucius Dougherty M, Konkolewicz D, Stewart P L, Steinmetz N F, Hore M J A, Pokorski J K. J. Am. Chem. Soc., 2017, 139 (9): 3312.

[77]
Kinnear C, Moore T L, Rodriguez-Lorenzo L, Rothen-Rutishauser B, Petri-Fink A. Chem. Rev., 2017, 117 (17): 11476.

[78]
Stevens C A, Kaur K, Klok H A. Adv. Drug Deliv. Rev., 2021, 174: 447.

[79]
Hu L, Zhang Y Y, Gao C Y. Progress in Chemistry, 2009, 21: 1254.

(胡玲, 张裕英, 高长有. 化学进展, 2009, 21: 1254.)

[80]
Konieczny S, Krumm C, Doert D, Neufeld K, Tiller J C. J. Biotechnol., 2014, 181: 55.

[81]
Sheng S L, Farinas E T. Catalysts, 2021, 11 (5): 606.

[82]
Zhao H. Biotechnol. Adv., 2020, 45: 107638.

[83]
Li Y, Zhang R, Xu Y. Int. J. Biol. Macromol., 2021, 168: 412.

[84]
Ismail A R, Kashtoh H, Baek K H. Int. J. Biol. Macromol., 2021, 187: 127.

[85]
Chado G R, Holland E N, Tice A K, Stoykovich M P, Kaar J L. ACS Catal., 2018, 8 (12): 11579.

[86]
Konieczny S, Leurs M, Tiller J C. ChemBioChem, 2015, 16 (1): 83.

[87]
Cummings C S, Murata H, Matyjaszewski K, Russell A J. ACS Macro Lett., 2016, 5 (4): 493.

[88]
Baker S L, Munasinghe A, Kaupbayeva B, Rebecca Kang N, Certiat M, Murata H, Matyjaszewski K, Lin P, Colina C M, Russell A J. Nat. Commun., 2019, 10 (1): 4718.

[89]
Takahashi K, Nishimura H, Yoshimoto T, Saito Y, Inada Y. Biochem. Biophys. Res. Commun., 1984, 121 (1): 261.

[90]
Inada Y, Takahashi K, Yoshimoto T, Kodera Y, Matsushima A, Saito Y. Trends Biotechnol., 1988, 6 (6): 131.

[91]
Matsushima A, Kodera Y, Hiroto M, Nishimura H, Inada Y. J. Mol. Catal. B: Enzym., 1996, 2 (1): 1.

[92]
Yoshihara E, Sasaki M, Nabil A, Iijima M, Ebara M. Molecules, 2022, 27 (3): 1051.

[93]
Steiert E, Ewald J, Wagner A, Hellmich U A, Frey H, Wich P R. Polym. Chem., 2020, 11 (2): 551.

[94]
Wang L, Gong C C, Yuan X Z, Wei G. Nanomaterials, 2019, 9 (2): 285.

[95]
Varlas S, Maitland G L, Derry M J. Polymers, 2021, 13 (16): 2603.

[96]
Shirinichi F, Ibrahim T, Rodriguez M, Sun H. J. Polym. Sci., 2023, 61 (8): 631.

[97]
Ko J H, Maynard H D. Chem. Soc. Rev., 2018, 47 (24): 8998.

[98]
Hannink J M, Cornelissen J J L M, Farrera J A, Foubert P, De Schryver F C, Sommerdijk N A J M, Nolte R J M. Angewandte Chemie, International Edition, 2001, 40 (24): 4732.

[99]
Liu Z Y, Dong C H, Wang X M, Wang H J, Li W, Tan J, Chang J. ACS Appl. Mater. Interfaces, 2014, 6 (4): 2393.

[100]
Huang A, Paloni J M, Wang A, Obermeyer A C, Sureka H V, Yao H, Olsen B D. Biomacromolecules, 2019, 20 (10): 3713.

[101]
Lam C N, Olsen B D. Soft Matter, 2013, 9 (8): 2393.

[102]
Dutta K, Kanjilal P, Das R, Thayumanavan S. Angewandte Chemie, International Edition, 2021, 60 (4): 1821.

[103]
Moatsou D, Li J, Ranji A, Pitto-Barry A, Ntai I, Jewett M C, O'Reilly R K. Bioconjugate Chem., 2015, 26 (9): 1890.

[104]
Bao C Y, Chen J, Li D, Zhang A T, Zhang Q. Polym. Chem., 2020, 11 (7): 1386.

[105]
Dong X H, Obermeyer A C, Olsen B D. Angewandte Chemie, International Edition, 2017, 56 (5): 1273.

[106]
Viana D B, Mathieu-Gaedke M, Leão N M, Böker A, Ferreira Soares D C, Glebe U, Tebaldi M L. J. Drug Deliv. Sci. Technol., 2023, 79: 103995.

[107]
Jiang Y Y, Wong S, Chen F, Chang T, Lu H X, Stenzel M H. Bioconjugate Chem., 2017, 28 (4): 979.

[108]
Bartnikowski M, Dargaville T R, Ivanovski S, Hutmacher D W. Prog. Polym. Sci., 2019, 96: 1.

[109]
Cummings C S, Fein K, Murata H, Ball R L, Russell A J, Whitehead K A. J. Control. Release, 2017, 255: 270.

[110]
Li Z C, Li G K, Hu Y L. Progress in Chemistry, 2017, 29: 1480.

(李子程, 李攻科, 胡玉玲. 化学进展, 2017, 29: 1480.)

[111]
Vanparijs N, De Coen R, Laplace D, Louage B, Maji S, Lybaert L, Hoogenboom R, De Geest B G. Chem. Commun., 2015, 51 (73): 13972.

[112]
Edwardson T G W, Levasseur M D, Tetter S, Steinauer A, Hori M, Hilvert D. Chem. Rev., 2022, 122 (9): 9145.

[113]
Rother M, Nussbaumer M G, Renggli K, Bruns N. Chem. Soc. Rev., 2016, 45 (22): 6213.

[114]
Nussbaumer M G, Duskey J T, Rother M, Renggli K, Chami M, Bruns N. Adv. Sci. (Weinheim, Ger.), 2016, 3 (10): 1600046.

[115]
Kim P H, Kim J, Kim T I, Nam H Y, Yockman J W, Kim M, Kim S W, Yun C O. Biomaterials, 2011, 32 (35): 9328.

[116]
Thambi T, Hong J, Yoon A R, Yun C O. Cancer Gene Ther., 2022, 29 (10): 1321.

[117]
Kim P H, Kim T I, Yockman J W, Kim S W, Yun C O. Biomaterials, 2010, 31 (7): 1865.

[118]
Sun Y P, Lv X Q, Ding P T, Wang L, Sun Y J, Li S, Zhang H M, Gao Z B. Acta Biomater., 2019, 97: 93.

[119]
Luo Y N, Wang X N, Du D, Lin Y H. Biomater. Sci., 2015, 3 (10): 1386.

[120]
Duret D, Haftek-Terreau Z, Carretier M, Berki T, Ladavière C, Monier K, Bouvet P, Marvel J, Leverrier Y, Charreyre M T, Favier A. Polym. Chem., 2018, 9 (14): 1857.

[121]
Duret D, Haftek-Terreau Z, Carretier M, Ladavière C, Charreyre M T, Favier A. Polym. Chem., 2017, 8 (10): 1611.

[122]
Berki T, Bakunts A, Duret D, Fabre L, Ladavière C, Orsi A, Charreyre M T, Raimondi A, van Anken E, Favier A. ACS Omega, 2019, 4 (7): 12841.

[123]
Zhang Y C, Gambardella A, Üçüncü M, Geng J, Clavadetscher J, Bradley M, Lilienkampf A. Chem. Commun., 2020, 56 (89): 13856.

[124]
Majonis D, Ornatsky O, Weinrich D, Winnik M A. Biomacromolecules, 2013, 14 (5): 1503.

[125]
Zhang L B, Zhao W G, Liu X Y, Wang G L, Wang Y, Li D, Xie L Z, Gao Y, Deng H T, Gao W P. Biomaterials, 2015, 64: 2.

[126]
Chatelain P, Malievskiy O, Radziuk K, Senatorova G, Abdou M O, Vlachopapadopoulou E, Skorodok Y, Peterkova V, Leff J A, Beckert M, Group T T G W. J. Clin. Endocrinol. Metab., 2017, 102 (5): 1673.

[127]
Sprogøe K, Mortensen E, Karpf D B, Leff J A. Endocr. Connect., 2017, 6 (8): R171.

[128]
Ebied A M, Patel K H, Cooper-DeHoff R M. Am. J. Med., 2020, 133 (6): 675.

[129]
Chowdary P, Fosbury E, Riddell A, Mathias M. J. Blood Med., 2016, 7: 187.

[130]
Javia A, Vanza J, Bardoliwala D, Ghosh S, Misra L A, Patel M, Thakkar H. Int. J. Pharm., 2022, 623: 121863.

[131]
Chen C J, Ng D Y W, Weil T. Prog. Polym. Sci., 2020, 105: 101241.

[132]
Mukhopadhyay A, Das T, Datta A, Sharma K P. Biomacromolecules, 2018, 19 (3): 943.

[133]
Brendel J C, Catrouillet S, Sanchis J, Jolliffe K A, Perrier S. Polym. Chem., 2019, 10 (20): 2616.

[134]
Brendel J C, Sanchis J, Catrouillet S, Czuba E, Chen M Z, Long B M, Nowell C, Johnston A, Jolliffe K A, Perrier S. Angewandte Chemie, International Edition, 2018, 57 (51): 16678.

[135]
Hu J, Wang G L, Zhao W G, Liu X Y, Zhang L B, Gao W P. Biomaterials, 2016, 96: 84.

[136]
Morgenstern J, Gil Alvaradejo G, Bluthardt N, Beloqui A, Delaittre G, Hubbuch J. Biomacromolecules, 2018, 19 (11): 4250.

[137]
Tucker B S, Stewart J D, Aguirre J I, Holliday L S, Figg C A, Messer J G, Sumerlin B S. Biomacromolecules, 2015, 16 (8): 2374.

[138]
Rose D A, Treacy J W, Yang Z J, Ko J H, Houk K N, Maynard H D. J. Am. Chem. Soc., 2022, 144 (13): 6050.

[139]
Diehl K L, Kolesnichenko I V, Robotham S A, Bachman J L, Zhong Y, Brodbelt J S, Anslyn E V. Nat. Chem., 2016, 8 (10): 968.

[140]
Liu B, Ianosi-Irimie M, Thayumanavan S. ACS Nano, 2019, 13 (8): 9408.

[141]
Zhao E L, Soltani M, Smith A K, Hunt J P, Knotts T A IV, Bundy B C. J. Biotechnol., 2022, 345: 55.

[142]
Li H, Yang Y Y, Li G P, Wang X, Hu J X, Rong M X, Rong J. Chinese Journal of Biologicals, 2021, 34: 941.

(李欢, 杨玉莹, 李国攀, 王席, 胡基雄, 荣明轩, 荣俊. 中国生物制品学杂志, 2021, 34: 941.).

[143]
Khalil A, Würthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, Möricke A, Zimmermann M, Smisek P, Zucchetti M, Nath C, Attarbaschi A, Von Stackelberg A, Gökbuget N, Rizzari C, Conter V, Schrappe M, Boos J, Lanvers-Kaminsky C. Haematologica, 2022, 107 (1): 49.

[144]
Risma K A, Edwards K M, Hummell D S, Little F F, Norton A E, Stallings A, Wood R A, Milner J D. J. Allergy Clin. Immunol., 2021, 147 (6): 2075.

[145]
Bigini P, Gobbi M, Bonati M, Clavenna A, Zucchetti M, Garattini S, Pasut G. Nat. Nanotechnol., 2021, 16 (11): 1169.

[146]
Zhang R S, Jain S, Rowland M, Hussain N, Agarwal M, Gregoriadis G. J. Diabetes Sci. Technol., 2010, 4 (3): 532.

[147]
Duncan R, Vicent M J. Adv. Drug Deliv. Rev., 2010, 62 (2): 272.

[148]
Smorodinsky N, Von Specht B U, Cesla R, Shaltiel S. Immunol. Lett., 1981, 2 (5/6): 305.

[149]
Viegas T X, Bentley M D, Harris J M, Fang Z H, Yoon K, Dizman B, Weimer R, Mero A, Pasut G, Veronese F M. Bioconjugate Chem., 2011, 22 (5): 976.

[150]
Thomas A, Müller S S, Frey H. Biomacromolecules, 2014, 15 (6): 1935.

Outlines

/